Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ping'an Ma
Nanomaterials Enable Spatiotemporally Controlled Ultrasound-Triggered Pyroptosis for Cancer Immunotherapy
Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. References 1, “Cancer Immunotherapy Comes of Age,” Science 355 (2017): 1220–1222, https://doi.org/10.1126/science.355.6330.1220.
Understanding Structure-Function Relationships of Nanoadjuvants for Enhanced Cancer Vaccine Efficacy
Review Jia Tan, Jia Tan State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022 China University of Science and Technology of China, Hefei, 230026 China Search for more papers by this author Binbin Ding, Corresponding Author Binbin Ding bbding@ciac.ac.cn State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022 China...
808 nm Near-Infrared light Controlled Dual-Drug Release and Cancer Therapy in vivo by Upconversion Mesoporous Silica Nanostructures
The design of stimuli-responsive drug delivery systems has attracted much attention to improve therapeutic efficacy for clinical applications. Here an 808 nm NIR light responsive dual-drug system was designed for cancer treatment both in vitro and in vivo. Mesoporous silica coated NaYF4:Yb0.4/Tm0.02@NaGdF4:Yb0.1@NaNdF4:Yb0.1 (UCNPs) with the core-shell structures (labeled as UCNPs@mSiO2) were prepared and loaded with antitumor drug doxorubicin (DOX).
Upconversion nanoparticles loaded with eIF4E siRNA and platinum(IV) prodrug to sensitize platinum based chemotherapy for laryngeal cancer and bioimaging
Eukaryotic translation initiation factor (eIF) 4E is a valuable marker in cancer prognostics in many human cancers. Silencing eIF4E via delivery of siRNA may be able to overcome chemoresistance. Cisplatin, used as a first-line anti-cancer reagent, has been widely accepted for its great success in clinical applications but it is restricted due to severe side effects such as nephrotoxicity, peripheral neuropathy, and hearing loss. Moreover, platinum drug resistance is a major obstacle to its use.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ping'an
Contact Ping'an, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack